With a new study in the journal Science Bulletin, researchers at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University have ...

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Ottimo Pharma Limited ("Ottimo"), an innovative, ...

AI Foundation Model for Tumor and Immune Biology to Guide Precision Patient Selection for Novel Bifunctional OTP-01 BostonGene, the developer of the leading AI foundation model for tumor and immune ...

As of Wednesday, January 07, CytomX Therapeutics, Inc.’s CTMX share price has surged by 6.40%, which has investors questioning if this is right time to sell.

Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients with prulacabtagene leucel (prula-cel, formerly ...

There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune ...

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to ...

The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).

Researchers found in mice that multiple nutrients and cancer cell characteristics work together to control the spread of ...

Scientists have uncovered how a vitamin A metabolite can suppress anti-cancer immunity. Scientists at the Princeton University Branch of the Ludwig Institute for Cancer Research have uncovered new ...

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the ...